Select Page

2024

KEYNOTE LECTURE: Too Little or Just Enough? The Role of Focal Therapy in ProtecT Era

KEYNOTE LECTURE: Too Little or Just Enough? The Role of Focal Therapy in ProtecT Era

Posted by | Sep 2024

Freddie Hamdy, MD, presents an insightful analysis of the role of focal therapy in the treatment of prostate cancer within the ProtecT era. He explores the balance between overtreatment and undertreatment, emphasizing the need for tailored approaches that maximize patient outcomes while minimizing unnecessary interventions.

Dr. Hamdy discusses the ProtecT trial’s findings, which highlight the benefits and limitations of active monitoring, surgery, and radiotherapy for localized prostate cancer. Focal therapy emerges as a promising middle ground. His presentation covers various focal therapy techniques, including high-intensity focused ultrasound (HIFU), cryotherapy, and focal laser ablation.

Dr. Hamdy stresses the importance of accurate patient selection, including diagnostic evaluations, multiparametric MRI, and targeted biopsies, for focal therapy. He also addresses the necessity of follow-up protocols including regular PSA testing and imaging.

Read More
Micro Ultrasound and MRI of the Prostate

Micro Ultrasound and MRI of the Prostate

Posted by | Sep 2024

Gerald L. Andriole, Jr., MD, is the global Chief Medical Officer at Prostatype Genomics. He previously was Professor and Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University. Throughout this 13-minute presentation, Dr. Andriole underscores the importance of staying abreast of technological advancements in urology, as they can transform prostate cancer care.

Read More
Integrating Care in Advanced Prostate Cancer

Integrating Care in Advanced Prostate Cancer

Posted by | Sep 2024

R. Jonathan Henderson, MD, addresses the economic burden and stress experienced by patients due to high treatment costs in advanced prostate cancer (APC) management. He stresses that this aspect of APC care often goes under-discussed.

In this 9-minute presentation, Dr. Henderson highlights direct costs such as medications, hospital stays, and physician fees, as well as indirect costs including lost income and travel expenses. He emphasizes that these financial strains can lead to treatment non-adherence, delayed care, and worsened clinical outcomes.

John W. Davis, MD, highlights the different ways integrated care models can be adopted across healthcare systems to enhance the management of advanced prostate cancer. By fostering a collaborative approach and eliminating barriers, Dr. Davis believes that the future of advanced prostate cancer care will be strengthened.

Read More
PARPi in mCRPC

PARPi in mCRPC

Posted by | Sep 2024

Daniel P. Petrylak, MD, Yale University Cancer Center, New Haven, Connecticut, summarizes the current and future role of PARP inhibitors in mCRPC, providing valuable insights into their clinical application and potential to improve patient outcomes.

In this 9-minute presentation, Dr. Henderson highlights direct costs such as medications, hospital stays, and physician fees, as well as indirect costs including lost income and travel expenses. He emphasizes that these financial strains can lead to treatment non-adherence, delayed care, and worsened clinical outcomes.

Dr. Henderson discusses various strategies and interventions to address these challenges, underscoring the importance of policy changes at the institutional and governmental levels to improve access to affordable care.

Read More

Join the GRU Community

- Why Join? -